Scholar Rock Holding Corp 8-K

What Happened

• On March 31, 2026, Scholar Rock Holding Corp (SRRK) announced it resubmitted its biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab to treat children and adults with spinal muscular atrophy (SMA). The company held a conference call at 8:00 a.m. ET the same day to discuss the update.

Key Details

• Resubmission date: March 31, 2026.
• Company expects FDA acceptance of the resubmission within 30 days and a review period of up to six months from the resubmission date.
• Anticipated PDUFA action date: late September 2026.
• Company referenced expectations tied to FDA reinspection of Catalent Indiana and included customary forward‑looking statement caution about risks and uncertainties.

Why It Matters

• A timely FDA acceptance and a PDUFA decision in late September 2026 are key regulatory milestones; a favorable decision would be required before commercial launch in the U.S. for apitegromab.
• The filing sets a near-term regulatory timeline investors can watch (acceptance within ~30 days; PDUFA by late Sept 2026), but the company cautioned these are forward‑looking and subject to risk, including matters tied to manufacturing inspections and other uncertainties.